Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Monitor Malta.
Press releases published on September 15, 2025
Supporting Heart Health in Our Communities
Toronto, ON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- LifeLabs is proud to support Heart Valve Voice Canada with a $5,000 donation to help raise awareness, detection, treatment, and support for Canadians affected by heart valve disease. Heart valve disease is a …
Parexel and Paradigm Health Partner to Expand Access and Efficiency in Clinical Trials
RALEIGH, N.C. and COLUMBUS, Ohio, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), and Paradigm Health, a company rebuilding the clinical research ecosystem, today announced a strategic partnership to …
Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
$4.7 million upfront with up to an additional approximately $8.3 million of potential aggregate gross proceeds upon the exercise in full of warrants BOTHELL, Wash., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc., (Nasdaq: COCP) (the “Company” or …
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.
Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company …
Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contre Inspire Medical Systems, Inc.
Nyxoah Entame une Procédure Judiciaire pour Violation de Brevets Contre Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgique – 15 septembre 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une …
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with …
Women’s Health Collective Canada Launches Vital Talks National Seminar Series with the Support of Vichy Laboratoires
TORONTO, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada (WHCC) is proud to announce the launch of Vital Talks, a new national online seminar series bringing together leading researchers, clinicians, and voices with lived experience to …
L’Association canadienne pour l’équité en santé des femmes (ACESF) lance la série de séminaires nationaux Conversations vitales avec le soutien de Vichy Laboratoires
TORONTO, 15 sept. 2025 (GLOBE NEWSWIRE) -- L’Association canadienne pour l’équité en santé des femmes (ACESF) est fière d’annoncer le lancement de Conversations vitales. Il s’agit d’une nouvelle série de séminaires nationaux en ligne rassemblant des …
AdCare Rhode Island Appoints New Executive Director as Facility Expansion Nears Completion to Serve More People Struggling with Addiction
NORTH KINGSTOWN, Rhode Island, Sept. 15, 2025 (GLOBE NEWSWIRE) -- AdCare Rhode Island has appointed Nicole Paliotti as its new Executive Director. As a trusted healthcare leader who has served the Rhode Island community for decades, Nicole brings extensive …
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up Enrollment for registrational Phase 3 portion of KYSA-6 trial in MG on track to initiate by year-end 2025 EMERYVILLE, Calif., Sept. 15, 2025 ( …
Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
New York, USA, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Immune Thrombocytopenic Purpura Market to Grow at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight The recent approval of Sanofi’s WAYRILZ has shifted the dynamics of the immune …
National Association of Specialty Pharmacy Congratulates Industry Award Winners at its Record-Breaking 2025 Annual Meeting & Expo
Washington, DC, Sept. 15, 2025 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) announces Industry Award winners at its record-breaking 2025 Annual Meeting …
Press release: SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM Ghent, Belgium, 15 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a …
Organic & Natural Health Leads First-Ever My Health Alliance Lobby Day on Capitol Hill
WASHINGTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- On Sept. 10, more than 50 citizen lobbyists representing a consortium of 15 national nonprofits and organizations gathered on Capitol Hill for the first My Health Alliance Lobby Day, organized by the Organic …
Smile Hair Clinic Becomes the First Hair Transplant Clinic in the World to Receive A-Rated Certificate from TEMOS
ISTANBUL, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Smile Hair Clinic has been awarded an A rating by TEMOS International Healthcare Accreditation, one of the most respected global organizations for quality and safety in healthcare. With this achievement, Smile …
ProteoNic Launches 2G UNic Transposon Platform to Support Superior Cell Line Productivity and Ease of Use
Leiden, The Netherlands – September 15, 2025 – ProteoNic, a leader in premium vector technology for biologics and cell and gene therapy, today announced the launch of its novel 2G UNic® transposon platform, available for licensing alongside the expansion …
Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting
Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAs Large …
Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test
PRESS RELEASE - 09/15/2025, 09:00 AM EDT Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test First-ever fully automated, sample-to-result, cartridge-based companion diagnostic test approved in the US for colorectal cancer patients Itasca (IL), …